Drugs / CMAB818
last change Dec 2022 re-read 2 minutes ago

CMAB818

Developed for
wet macular degeneration
Investigated by
Shanghai Biomabs Pharmaceutical Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04884399 Jun 2021 → Dec 2022 wet macular degeneration Shanghai Biomabs Pharmaceutical Co., Ltd. Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CMAB818 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04884399